ProfileGDS5678 / 1442893_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 38% 38% 37% 39% 43% 39% 38% 38% 39% 38% 38% 39% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9487640
GSM967853U87-EV human glioblastoma xenograft - Control 22.8752938
GSM967854U87-EV human glioblastoma xenograft - Control 32.8792938
GSM967855U87-EV human glioblastoma xenograft - Control 42.7826637
GSM967856U87-EV human glioblastoma xenograft - Control 52.8355339
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0809843
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9517339
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8589238
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8547938
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8717139
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8588138
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.838638
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8956139
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8676238